Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 6/20 | 0.91 |
| ▸ | CYP17A1 | P05093 | 5/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.66 |
| ▸ | G6PD | P11413 | 4/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | GUSB | P08236 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | ESR1 | P03372 | 1/20 | 0.54 |
| ▸ | AR | P10275 | 1/20 | 0.54 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL138937 | 0.96 | SHBG (1.00) | SHBGCYP17A1ALDH1A1CYP2C9HIF1A | |
| SCHEMBL27633183 | 0.96 | SHBG (1.00) | SHBGCYP17A1ALDH1A1CYP2C9HIF1A | |
| SCHEMBL27808104 | 0.96 | SHBG (1.00) | SHBGCYP17A1ALDH1A1CYP2C9HIF1A | |
| SCHEMBL18373712 | 0.96 | SHBG (1.00) | SHBGCYP17A1ALDH1A1CYP2C9HIF1A | |
| SCHEMBL658688 | 0.96 | SHBG (1.00) | SHBGCYP17A1ALDH1A1CYP2C9HIF1A | |
| SCHEMBL20457510 | 0.96 | SHBG (1.00) | SHBGCYP17A1ALDH1A1CYP2C9HIF1A | |
| SCHEMBL142941 | 0.96 | SHBG (1.00) | SHBGCYP17A1ALDH1A1CYP2C9HIF1A | |
| SCHEMBL735471 | 0.96 | SHBG (1.00) | SHBGCYP17A1ALDH1A1CYP2C9HIF1A | |
| SCHEMBL17776491 | 0.96 | SHBG (1.00) | SHBGCYP17A1ALDH1A1CYP2C9HIF1A | |
| SCHEMBL31086698 | 0.88 | SHBG (0.85) | SHBGCYP17A1ALDH1A1CYP2C9HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080159971-A1 | USE OF DHEA OR PRECURSORS OR METABOLIC DERIVATIVES THEREOF AS A DEPIGMENTING AGENT | L'ORéAL S.A. (FR) | 2008-07-03 | — | — | US | claimed |
| US-7351699-B1 | Use of DHEA or precursors or metabolic derivatives thereof as a depigmenting agent | L'OREAL (FR) | 2008-04-01 | — | — | US | claimed |
| US-20040009196-A1 | Topically applying dehydroepiandrosterone to prevent intrinsic or photoinduced skin aging | L'OREAL (FR) | 2004-01-15 | — | — | US | claimed |
| US-20030083323-A1 | Oral use of dehydroepiandrosterone and some of its derivatives as pigmentation regulators | ASSITANCE PUBLIQUE - HOPITAUX DE PARIS (FR) | 2003-05-01 | — | — | US | claimed |
| US-20030059451-A1 | Use of orally administered dehydroepiandrosterone, precursors and derivatives thereof in order to improve the papery aspect of the skin | ASSITANCE PUBLIQUE - HOPITAUX DE PARIS (FR) | 2003-03-27 | — | — | US | claimed |
| US-20030050293-A1 | Use of dehydroepiandrosterone, its precursors and derivatives, by oral administration, as hydrating agents with direct action | ASSITANCE PUBLIQUE - HOPITAUX DE PARIS (FR) | 2003-03-13 | — | — | US | claimed |
| US-20020197289-A1 | Compositions and methods for combating the appearance of ageing | L'OREAL (FR) | 2002-12-26 | — | — | US | claimed |
| US-6486147-B2 | FOR PREVENTING OR TREATING CHRONOLOGICAL OR ACTINIC AGEING OF SKIN | L'OREAL (FR) | 2002-11-26 | — | — | US | claimed |
| US-20010044430-A1 | Cosmetic composition containing a steroid and a 2-alkylalkanol or an ester thereof | L'OREAL (FR) | 2001-11-22 | — | — | US | claimed |
| US-11730682-B2 | Self-standing cosmetic sheet | L'OREAL (FR) | 2023-08-22 | — | — | US | disclosed |
| EP-2836187-B1 | SELF-STANDING COSMETIC SHEET | OREAL (FR) | 2021-12-08 | — | — | EP | disclosed |
| EP-2683351-B1 | USE OF A 2-METHYLSUCCINIC ACID DIESTER DERIVATIVE AS SOLVENT IN COSMETIC COMPOSITIONS; COSMETIC COMPOSITIONS CONTAINING THE SAME | OREAL (FR) | 2019-10-16 | — | — | EP | disclosed |
| US-20180235849-A1 | SELF-STANDING COSMETIC SHEET | L'OREAL (FR) | 2018-08-23 | — | — | US | disclosed |
| US-9949897-B2 | Self-standing cosmetic sheet | L'OREAL (FR) | 2018-04-24 | — | — | US | disclosed |
| US-20030027864-A1 | Compositions comprising a compound of low solubility and a lipophilic amino acid derivative, uses thereofand process for dissolving a compound of low solubility | L'OREAL (FR) | 2003-02-06 | — | — | US | disclosed |
| US-20020197288-A1 | Compositions for the skin comprising fibers and ubiquinones and methods of using the same | L'OREAL (FR) | 2002-12-26 | — | — | US | disclosed |
| US-20020197289-A1 | Compositions and methods for combating the appearance of ageing | L'OREAL (FR) | 2002-12-26 | — | — | US | disclosed |
| US-6486147-B2 | FOR PREVENTING OR TREATING CHRONOLOGICAL OR ACTINIC AGEING OF SKIN | L'OREAL (FR) | 2002-11-26 | — | — | US | disclosed |
| US-20020142017-A1 | Suspension of nanospheres of lipophilic active principle stabilized with water-dispersible polymers | L'OREAL (FR) | 2002-10-03 | — | — | US | disclosed |
| US-20010044430-A1 | Cosmetic composition containing a steroid and a 2-alkylalkanol or an ester thereof | L'OREAL (FR) | 2001-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080159971-A1 | USE OF DHEA OR PRECURSORS OR METABOLIC DERIVATIVES THEREOF AS A DEPIGMENTING AGENT | HSD17B11, SHBG, CYP21A2 | SHBG 2/4885CYP17A1 9/4885ALDH1A1 201/4885 |
| US-20010044430-A1 | Cosmetic composition containing a steroid and a 2-alkylalkanol or an ester thereof | NOTUM, HSD3B2, HSD3B1 | SHBG 7/4885CYP17A1 11/4885ALDH1A1 133/4885 |
| US-20020197289-A1 | Compositions and methods for combating the appearance of ageing | CYP24A1, CYP27B1, CYP2R1 | SHBG 129/4885CYP17A1 70/4885ALDH1A1 1440/4885 |
| US-20020142017-A1 | Suspension of nanospheres of lipophilic active principle stabilized with water-dispersible polymers | LIPA, S100P, LSS | SHBG 3515/4885CYP17A1 919/4885ALDH1A1 1344/4885 |
| US-20180235849-A1 | SELF-STANDING COSMETIC SHEET | CUTA, DSG1, SUCLG1 | SHBG 554/4885CYP17A1 917/4885ALDH1A1 981/4885 |
| US-11730682-B2 | Self-standing cosmetic sheet | CUTA, DSG1, SUCLG1 | SHBG 554/4885CYP17A1 917/4885ALDH1A1 981/4885 |
| US-20040009196-A1 | Topically applying dehydroepiandrosterone to prevent intrinsic or photoinduced skin aging | NR5A1, CYP17A1, SRD5A1 | SHBG 4/4885CYP17A1 2/4885ALDH1A1 361/4885 |
| US-20030027864-A1 | Compositions comprising a compound of low solubility and a lipophilic amino acid derivative, uses thereofand process for dissolving a compound of low solubility | AASDHPPT, AADAT, ALAD | SHBG 16/4885CYP17A1 8/4885ALDH1A1 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.